

# Relationship Between Autonomic Neuropathy, 24-h Blood Pressure Profile, and Nephropathy in Normotensive IDDM Patients

VINCENZA SPALLONE, MD, PHD  
SERGIO GAMBARDILLA, MD  
MARIA R. MAIELLO, MD

ANGELA BARINI, MD  
SIMONA FRONTONI, MD  
GUIDO MENZINGER, MD

**OBJECTIVE** — To evaluate the relationship between autonomic neuropathy, nephropathy, and 24-h blood pressure (BP) pattern in insulin-dependent diabetes mellitus (IDDM).

**RESEARCH DESIGN AND METHODS** — We studied 30 normotensive IDDM patients without overt nephropathy, divided into two groups and matched for age, duration of diabetes, and HbA<sub>1c</sub>, according to the presence of cardiovascular autonomic neuropathy. We simultaneously measured 24-h BP and urinary albumin excretion rate (UAE) on urine collections timed overnight and at 2-h intervals during the day.

**RESULTS** — Mean day and night systolic and diastolic BP values did not significantly differ between the groups. Mean night albuminuria was significantly higher in patients with autonomic neuropathy than in those without ( $61.4 \pm 104.6$  [mean  $\pm$  SD] vs.  $16 \pm 25.2$   $\mu\text{g}/\text{min}$ ,  $P < 0.04$ ). The percentages day-night changes in systolic BP, diastolic BP, and UAE were significantly lower in neuropathic patients (systolic BP:  $2.4 \pm 7.7$  vs.  $9.6 \pm 4.2\%$ ,  $P < 0.001$ ; diastolic BP:  $8.4 \pm 6.9$  vs.  $15.5 \pm 5.4\%$ ,  $P < 0.002$ ; UAE:  $-8 \pm 99.4$  vs.  $49.3 \pm 29.4\%$ ,  $P < 0.02$ ) and were inversely related to autonomic score, index of autonomic neuropathy degree ( $r = -0.54$ ,  $P < 0.002$ ;  $r = -0.58$ ,  $P < 0.001$ ; and  $r = -0.53$ ,  $P < 0.005$ , respectively). In patients with autonomic neuropathy, 2-h day periods and day and night UAE were more strongly related, respectively, to mean 2-h day periods ( $r = 0.58$ ,  $P < 0.0001$ ), day systolic BP ( $r = 0.67$ ,  $P < 0.04$ ), and night systolic BP ( $r = 0.69$ ,  $P < 0.04$ ) than in patients without autonomic neuropathy (2-h day periods:  $r = 0.32$ ,  $P < 0.001$ ; day:  $r = 0.37$ , NS; night:  $r = 0.35$ , NS).

**CONCLUSIONS** — Autonomic neuropathy in IDDM patients is associated with reduced nocturnal falls in BP and UAE and with a stronger relationship of UAE to systolic BP. We suggest a pathogenetic role of autonomic neuropathy in the development of diabetic nephropathy through changes in nocturnal glomerular function and by enhanced kidney vulnerability to hemodynamic effects of BP.

From the Department of Internal Medicine, Endocrinology (V.S., S.G., M.R.M., S.F., G.M.), Tor Vergata University, Rome, Italy; and the Institute of Biochemistry (A.B.), Catholic University, Rome, Italy.

Address correspondence and reprint requests to Vincenza Spallone, MD, PhD, Dipartimento di Medicina Interna, Università di Tor Vergata, Complesso Integrato Columbus, via della Pineta Sacchetti 506, 00168 Rome, Italy.

Received for publication 12 August 1993 and accepted in revised form 20 January 1994.

IDDM, insulin-dependent diabetes mellitus; BP, blood pressure; ABPM, ambulatory 24-h blood-pressure monitoring; UAE, urinary albumin excretion.

Clinical and epidemiological studies have shown an association between autonomic neuropathy and nephropathy in insulin-dependent diabetes mellitus (IDDM) (1–4). This finding is of prognostic interest, because both of these diabetic complications are associated with a higher mortality rate (5–9).

A pathogenetic significance of the association between diabetic neuropathy and nephropathy has been proposed preliminarily by some authors (4,10,11) and supported by the knowledge of a rich innervation of the kidney and of a neural control of renal function (12–16). Moreover, abnormalities in kidney function have also been described in conditions of autonomic failure other than diabetic neuropathy (17,18).

The pathogenesis of diabetic nephropathy is not wholly understood, and the temporal link between hypertension and nephropathy is still under debate. Ambulatory 24-h blood-pressure monitoring (ABPM) has been proved to be a useful tool for recording blood pressure (BP). Compared to casual BP, ABPM is both more strongly related to target organ damage of hypertension and to albuminuria and more sensitive in detecting an early increase in BP load in diabetic patients (19–21). Moreover, ABPM has allowed us to detect in diabetic patients unsuspected abnormalities of the BP circadian rhythm and to relate them to autonomic (22–24) or renal dysfunction (21,25). More information on the relationship between autonomic neuropathy, BP, and nephropathy might lead to a better pathogenetic understanding of hemodynamic changes of diabetic nephropathy.

We performed this study to evaluate in normotensive IDDM patients without clinical nephropathy the relationship between autonomic neuropathy, nephropathy assessed by albuminuria, and the 24-h BP pattern.

## RESEARCH DESIGN AND METHODS

Thirty subjects with IDDM participated in the study. Informed

**Table 1—Clinical parameters and cardiovascular reflex tests of IDDM patients without and with autonomic neuropathy (AN)**

IDDM patients	Without AN	With AN	P value
n	18	12	
Age (years)	39.3 ± 8.9	41.5 ± 12.7	NS
Sex (M/F)	9/9	7/5	NS
Diabetes duration (years)	16 ± 9.1	18.5 ± 8.2	NS
Body mass index (kg/m <sup>2</sup> )	23.1 ± 2.7	22.9 ± 3.5	NS
Insulin (U/day)	43.2 ± 14	39.4 ± 12.5	NS
HbA <sub>1c</sub> (%)	8.2 ± 1.8	9.2 ± 1.9	NS
Serum creatinine (μM)	73.2 ± 20.9	73.1 ± 20.9	NS
Retinopathy (absent/background/proliferative)	11/6/1	4/6/2	NS
Casual systolic BP (mmHg)	116.16 ± 13.84	114.66 ± 13.73	NS
Casual diastolic BP (mmHg)	72.11 ± 5.63	72.27 ± 10.36	NS
Deep breathing (breaths/min)	22.19 ± 7.37	7.68 ± 7.23	0.0001
Lying to standing	1.15 ± 0.10	0.97 ± 0.05	0.0001
Valsalva ratio	1.46 ± 0.35	1.21 ± 0.2	0.02
Postural hypotension (mmHg)	3.62 ± 7.27	17.85 ± 14.18	0.001
Autonomic score	0.67 ± 0.69	4.75 ± 1.66	0.0001

Data are means ± SD.

consent was obtained from all participants. They were consecutively recruited from the diabetic clinic of the University of Rome Tor Vergata. Inclusion criteria were <60 years of age; values of casual BP in the normal range according to World Health Organization criteria ( $\leq 140/90$  mmHg); and the absence of macroalbuminuria (urinary albumin excretion (UAE)  $\geq 200$  μg/min), urinary infection, and any clinically relevant acute or chronic disease other than diabetes, especially if it affected renal, respiratory, or cardiovascular function. No subject was taking any drug other than insulin. Sixteen were men and 14 were women. Age (mean ± SD) was  $40.2 \pm 10.4$  years (range 23–59). Duration of diabetes was  $17 \pm 8.7$  years (range 1–38). HbA<sub>1c</sub> was  $8.6 \pm 1.7\%$ , measured with chromatography (reference range 5–8%). Creatininemia was  $73.2 \pm 20.6$  μM. Nonproliferative retinopathy was present in 12 patients and proliferative retinopathy in 3 patients.

Diabetic patients were compared to a control group of 29 age-matched normal subjects (21 men and 8 women,  $42.8$

$\pm 11.1$  years of age) for 24-h BP monitoring.

Autonomic function was explored by deep breathing, lying to standing, Valsalva maneuver, and postural hypotension tests, performed and evaluated according to standard procedures (26). To quantify the combined results from the tests, an autonomic score was calculated from the sum of scores given for each of the four tests (0 for a normal result, 1 for a borderline result, and 2 for an abnormal result) (27). This score ranged from 0 to 8. Patients with at least one abnormal cardiovascular test were considered to have autonomic neuropathy, and those with less than one positive test were considered to be free of neuropathy. In more detail, 18 patients had all normal tests or one or two borderline results with an autonomic score of 0–2, 5 patients had one abnormal test and one borderline test with an autonomic score of 3, and 7 patients had more than two abnormal tests with an autonomic score of 5–7. Clinical data and cardiovascular tests of diabetic patients with and without autonomic neuropathy are given in Table 1. No sig-


nificant difference in any clinical parameter was found.

Noninvasive ABPM was performed using an oscillometric recorder (SpaceLabs 90202, Redmond, WA), a device of proven accuracy, satisfying the validation requirements for ABPM systems (28). The device was programmed to measure BP every 20 min for 24 h. Recordings were started between 0800 and 0900. Patients were hospitalized; they were free to move in the hospital area during the monitoring and were requested to comply with hospital routines and to record their activities and the time of waking up and going to bed. BP recordings were automatically edited and then visually screened for artefactual readings (29). Systolic and diastolic BP measurements were averaged for each hour, for 2-h intervals during the day, and for the day (0800–2200) and the night (2200–0800) periods. In addition, the percentage change in BP from day to night ( $\Delta$  day-night BP) was calculated as:  $(\text{day BP} - \text{night BP}) \times 100/\text{day BP}$ . The same evaluation was performed in the group of control subjects.

Albumin concentration was measured by a double antibody radioimmunoassay (Albumin RIA 100, Pharmacia, Uppsala, Sweden) on urine collections timed overnight and at 2-h intervals during the day. Samples were simultaneous to 24-h BP monitoring and were stored at  $-20^\circ\text{C}$  until the test procedure. The detection limit of assay was  $\leq 0.4$  mg/L, and interassay coefficients of variation ranged from 3–7%. UAE was calculated for each 2-h period during the day, for the day (0800–2200) and the night (2200–0800) periods, and for the 24-h period. In addition, the percentage change in UAE from day to night ( $\Delta$  day-night UAE) was calculated as:  $(\text{day UAE} - \text{night UAE}) \times 100/\text{day UAE}$ . Similarly, 24-h, day, night, and  $\Delta$  day-night urine volumes were measured.

### Statistical analysis

Data are expressed as means ± SD, unless specified differently. Unpaired Student's t




**Figure 1**—Mean hourly systolic (●, ■) and diastolic (○, □) BP in IDDM patients without autonomic neuropathy (●, ○) and with autonomic neuropathy (■, □). The x-axis indicates clock hours from 0100 to 2400. Values are means ± SE. \**P* < 0.05 between the groups for systolic and diastolic BP.

test was used to compare diabetic patients to control subjects and diabetic patients with neuropathy to those without. Linear regression analysis was used to relate different variables. All statistical analyses were done using the program StatView II (Abacus Concepts, Berkeley, CA) on a Macintosh IICI computer. A value of *P* < 0.05 was considered significant.

**RESULTS**—Control subjects displayed a clear decrease in BP during the night hours and an increase that started at about 0700 and peaked at about 1100. Diabetic patients compared with control subjects showed a trend to lower mean hourly BP during the day, with a significant difference in systolic BP at 0800 (*P* < 0.02), 0900 (*P* < 0.01), and 1300 (*P* < 0.02) and in diastolic BP at 0900 (*P* < 0.02), 1300 (*P* < 0.04), and 2000 (*P* < 0.03). Figure 1 shows 24-h profiles of mean hourly systolic and diastolic BP in diabetic subjects with and without neuropathy. Diabetic patients with neuropathy compared with those without showed significantly higher systolic BP at 0500 and higher diastolic BP at 0300, 0600, and 2400.

No differences were seen in average 24-h and day and night systolic and diastolic BP between diabetic patients and control subjects (Table 2), whereas Δ



**Figure 2**—The Δ day-night in systolic BP, diastolic BP, and UAE in IDDM patients without and with autonomic neuropathy. Values are means ± SE. \**P* < 0.02, \*\**P* < 0.002, \*\*\**P* < 0.001 among the groups.

day-night systolic BP was significantly reduced in diabetic subjects (*P* < 0.002). When considering diabetic subjects with and without neuropathy separately, we observed that only those with neuropathy displayed significant lower Δ day-night systolic BP in comparison with control subjects (*P* < 0.0001). In addition, diabetic patients with neuropathy showed significant reductions in Δ day-night systolic and diastolic BP when compared with diabetic patients without neuropathy (*P* < 0.001 and *P* < 0.002, respectively) (Fig. 2).

**Table 2**—Average 24-h, day, and night values of systolic and diastolic BP, and average Δ day-night systolic and diastolic BP in control subjects, in all IDDM patients and in IDDM patients without and with autonomic neuropathy (AN)

	Control subjects	IDDM patients		
		All	Without AN	With AN
<i>n</i>	29	30	18	12
<b>Systolic BP</b>				
24-h (mmHg)	112.04 ± 10.10	109.84 ± 13.02	109.49 ± 11.42	110.37 ± 15.65
day (mmHg)	117.87 ± 10.59	113.14 ± 13.35	114.26 ± 12.38	111.45 ± 15.08
night (mmHg)	104.52 ± 10.36	105.43 ± 14.03	103.14 ± 10.77	108.87 ± 17.84
Δ day-night (%)	11.30 ± 4.62	6.70 ± 6.76*	9.58 ± 4.22†	2.37 ± 7.68‡
<b>Diastolic BP</b>				
24-h (mmHg)	72.06 ± 6.69	70.54 ± 7.69	70.10 ± 6.78	71.20 ± 9.17
day (mmHg)	76.60 ± 6.69	74.50 ± 7.85	74.93 ± 6.87	73.84 ± 9.41
night (mmHg)	66.31 ± 7.00	65.06 ± 8.31	63.28 ± 6.90	67.73 ± 9.76
Δ day-night (%)	13.54 ± 6.00	12.67 ± 6.90	15.50 ± 5.39§	8.43 ± 6.93

Data are means ± SD. \**P* < 0.002 vs. control subjects; †*P* < 0.001 vs. IDDM patients with AN; ‡*P* < 0.0001 vs. control subjects; §*P* < 0.002 vs. IDDM patients with AN; ||*P* < 0.01 vs. control subjects.

**Table 3—Average 24-h, day, night, and  $\Delta$  day-night UAE and urine volume in IDDM patients without and with autonomic neuropathy (AN)**

	IDDM patients		P value
	Without AN	With AN	
n	18	12	
UAE			
24-h ( $\mu\text{g}/\text{min}$ )	22.03 $\pm$ 37.50	50.40 $\pm$ 75.34	NS
day ( $\mu\text{g}/\text{min}$ )	26.33 $\pm$ 46.16	53.55 $\pm$ 76.68	NS
night ( $\mu\text{g}/\text{min}$ )	16.04 $\pm$ 25.24	61.41 $\pm$ 104.56	0.04
$\Delta$ day-night (%)	49.29 $\pm$ 29.37	-7.98 $\pm$ 99.41	0.02
Urine volume			
24-h (ml)	1581.11 $\pm$ 479.89	1863.5 $\pm$ 455.79	NS
day (ml)	1000.52 $\pm$ 345.21	1055.83 $\pm$ 545.72	NS
night (ml)	626.11 $\pm$ 351.77	932 $\pm$ 285.80	0.01
$\Delta$ day-night (%)	34.86 $\pm$ 43.27	-31.50 $\pm$ 93.19	0.01

Data are means  $\pm$  SD.

0.02) (Table 3 and Fig. 2). Moreover,  $\Delta$  day-night UAE was inversely related to the autonomic score ( $r = -0.53$ ,  $P < 0.005$ ) and to postural hypotension ( $r = -0.39$ ,  $P < 0.05$ ), and positively related to  $\Delta$  day-night systolic BP ( $r = 0.45$ ,  $P < 0.02$ ).

The 2-h day periods UAE, day UAE, and night UAE were found to be more strongly related to average synchronous 2-h day periods systolic and diastolic BP ( $r = 0.58$ ,  $P < 0.0001$  and  $r = 0.51$ ,  $P < 0.0001$ ), day systolic and diastolic BP ( $r = 0.67$ ,  $P < 0.02$  and  $r = 0.68$ ,  $P < 0.02$ ), and night systolic and diastolic BP ( $r = 0.69$ ,  $P < 0.04$  and  $r = 0.64$ , NS) in neuropathic patients than in diabetic subjects without neuropathy (systolic BP: 2-h day:  $r = 0.32$ ,  $P < 0.001$ ; day:  $r = 0.37$ , NS; night:  $r = 0.35$ , NS; diastolic BP: 2-h day:  $r = 0.36$ ,  $P < 0.0001$ ; day:  $r = 0.44$ , NS; night:  $r = 0.54$ ,  $P < 0.02$ ). The slopes of the regression lines between UAE and systolic BP of 2-h day periods were 3.09 for neuropathic and 0.98 for non-neuropathic subjects, with a significant difference between them ( $P < 0.001$ ), as evaluated by the method of comparison of regression lines (Fig. 3).

As shown in Table 3, night urine volume was significantly greater and  $\Delta$


day-night urine volume was significantly smaller in patients with neuropathy than in those without ( $P < 0.01$  for both). The  $\Delta$  day-night volume was related to autonomic score ( $r = -0.59$ ,  $P < 0.001$ ), to postural hypotension ( $r = -0.44$ ,  $P < 0.02$ ), to  $\Delta$  day-night systolic BP ( $r = 0.57$ ,  $P < 0.002$ ), and to  $\Delta$  day-night UAE ( $r = 0.68$ ,  $P < 0.0001$ ).

**CONCLUSIONS**— Twenty-four-hour BP monitoring has shown an altered profile in normotensive IDDM patients compared with control subjects. This abnormality seems to be related to the presence of autonomic neuropathy, because diabetic subjects with cardiovascular autonomic neuropathy display a blunted nocturnal BP fall in comparison with those without autonomic neuropathy, and the day-night change in BP is related to the degree of cardiovascular reflex test impairment and, in particular, to the postural hypotension test.

A decrease in nocturnal BP fall or higher nocturnal BP has been observed in IDDM patients with different degrees of diabetic nephropathy (21,25). Whether diabetic nephropathy itself or an associated autonomic dysfunction was responsible for the altered circadian pattern was not fully explored in those studies. In this

study, none of the diabetic patients was hypertensive or macroalbuminuric, and the percentage of microalbuminuric patients was not different among diabetic subjects with and those without autonomic neuropathy. Thus, the abnormality in BP profile in neuropathic patients is probably not attributable to hypertension or diabetic nephropathy, but it is possibly dependent on autonomic dysfunction, according to previous reports on patients with autonomic failure (30) and diabetic autonomic neuropathy (22–24). Moreover, in diabetic patients with autonomic neuropathy, the normal circadian rhythm of sympathovagal interaction is lost, with a blunted vagal increase and a sympathetic relative prevalence during the night (31). Finally, we have found in diabetic patients a clear correlation between the decrease in nocturnal BP fall and the prevalence of sympathetic tone at night (32).

In this study, diabetic patients



**Figure 3—Correlation between 2-h day periods for UAE and systolic BP in IDDM patients without (A) and with autonomic neuropathy (B). The slopes between UAE and BP are significantly different for the two groups ( $P < 0.001$ ), being steeper in patients with neuropathy. A:  $r = 0.32$ ,  $P < 0.001$ . B:  $r = 0.58$ ,  $P < 0.0001$ .**

with autonomic neuropathy displayed night UAE values slightly but significantly higher and a day-night change in UAE significantly lower than those in diabetic subjects without neuropathy. A clinical association between neuropathy and nephropathy in diabetes has been documented in some studies (1–4,33). So far, only a few studies have suggested a pathogenetic relationship between these two diabetic complications, starting with the report of an increase in renal flow in IDDM patients with autonomic neuropathy (34). Some evidence of a neural regulatory function of kidney exists. After renal nerve stimulation in rats, vascular resistances increase, with a consequent reduction in both renal blood flow and glomerular filtration rate, and proximal water and sodium reabsorption is enhanced. However, although diuretic and natriuretic effects of denervation show up well in experimental conditions, hemodynamic consequences of renal denervation are less clear (13,15,16). On the other hand, observations in human autonomic dysfunction fit well with a possible pathogenetic significance of the association between autonomic neuropathy and nephropathy. Excessive nocturnal diuresis and natriuresis have been described both in nondiabetic autonomic failure (17) and in diabetic autonomic neuropathy (35). Higher nocturnal UAE and nocturnal sodium excretion rates have been reported in neuropathic insulin-treated patients and have been attributed to a derangement of nocturnal renal hemodynamics and glomerulotubular balance (11). Finally, in a 10-year prospective study, glomerular filtration rate decreased more than expected in IDDM patients with autonomic neuropathy (36). Decrements in intraglomerular pressure during the day and increments at night were the hypothesized connecting link between autonomic neuropathy and the deterioration in glomerular filtration rate.

In this study, compared with non-neuropathic diabetic subjects, patients with neuropathy displayed a lower nocturnal fall of UAE that is correlated to the

degree of autonomic neuropathy. In the same patients, an altered circadian pattern of BP also occurs. The correlation between the day-night change in systolic BP and changes in UAE and urine volume might be interpreted as reflecting some possible causal connection. That is, a reduced fall in BP during the night might be responsible for increased nocturnal urine output and albuminuria. Nevertheless, because the day-night changes in BP, UAE, and urine volume are strongly related to the degree of autonomic impairment, the possibility that autonomic neuropathy acts directly on all three parameters exists, e.g., by blunting the night BP fall, by increasing renal blood flow and glomerular filtration rate, and by impairing the tubular water and sodium reabsorption. According to this line of reasoning, the relationship between the altered day-night patterns of BP, UAE, and urine volume would be secondary, at least in part, to the widespread influence of autonomic neuropathy. The relationship of these day-night patterns to the postural hypotension test might further involve the dysfunction of reflex postural adjustments, as previously suggested (35).

This study brings out another interesting aspect, that of the relationship between BP and nephropathy. As in essential hypertension (37,38), in IDDM patients, as well, a positive correlation between albuminuria and BP levels has been described (39,40). Night UAE has been found to be related to day and night systolic BP in a group of normo- and microalbuminuric IDDM patients (25) and, in another study, in microalbuminuric patients to 24-h and day diastolic BP and to night systolic BP (21). No assessment of autonomic function was made in these studies. In this study, for the first time, BP and UAE have been evaluated simultaneously over the whole 24-h period and related to autonomic neuropathy. This approach has allowed us to find that in neuropathic patients 2-h day periods and day and night UAE are more strongly related to mean 2-h day, day, and night sys-

tolic BP, respectively, than in patients without neuropathy. In other words, for a certain value of systolic BP, neuropathic patients would have higher UAE than non-neuropathic patients. Two interpretations for this finding are possible. The simpler explanation is that neuropathic patients could have a more advanced nephropathy compared with patients without neuropathy and that, in patients with more developed nephropathy, BP could be more effective on albumin excretion. There were, however, no significant differences in 24-h UAE between diabetic patients with and diabetic patients without autonomic neuropathy, and the small number of microalbuminuric patients was equally distributed between them. In addition, in the study by Hansen et al. (25), the relationship between UAE and BP was similar in micro- and normoalbuminuric patients. Nevertheless, because we did not perform more sensitive assessment of renal function in this study, we cannot exclude a different degree of nephropathy between the two groups of diabetic patients. The second possible explanation comes from and supports the suggestion of a pathogenetic relationship between diabetic neuropathy and nephropathy. The loss of nervous control of renal function might make the kidneys more vulnerable to the hemodynamic effects of systemic BP. This could be a result of the deprivation of compensative mechanisms, under autonomic nervous system control, active on the glomerular hemodynamics. In a recent study, Krolewski et al. (41) pointed out that autonomic neuropathy may be a strong risk factor for early-onset proliferative retinopathy, suggesting a possible role for autonomic neuropathy in the development of retinal blood flow abnormalities. In a similar way, hemodynamic changes could follow autonomic denervation in the kidney and favor the development and/or progression of nephropathy.

In conclusion, autonomic neuropathy in IDDM patients is associated with a reduced nocturnal fall in BP and in UAE and with a stronger relationship of

UAE to systolic BP. These findings might shed light on the known association between diabetic neuropathy and nephropathy. We suggest a pathogenetic role of autonomic neuropathy in the development of diabetic nephropathy through changes in nocturnal glomerular function and by enhancement of kidney vulnerability to the hemodynamic effects of BP.

**Acknowledgments**—S.F. was supported by a Postgraduate Fellowship Award 393365 from the Juvenile Diabetes Foundation International.

Part of the study was presented at the 27th annual meeting of the European Association for the Study of Diabetes, Dublin, Ireland, September 1991 and published in abstract form (Spallone V, Gambardello S, Felici MG, Maiello MR, Frontini S, Lala A, Menzinger G: 24-h blood pressure profile and albuminuria in diabetic patients with and without autonomic neuropathy. *Diabetologia* 34 [Suppl. 2]:A160, 1991).

## References

- Zander EZ, Schulz B, Heinke P, Grimberger E, Zander G, Gottschling DH: Importance of cardiovascular autonomic dysfunction in IDDM subjects with diabetic nephropathy. *Diabetes Care* 12:259–264, 1989
- Neil HAW, Thompson AV, John S, McCarthy ST, Mann JI: Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. *Diabetic Med* 6:20–24, 1989
- Pontuch P, Vozar J, Potocky M, Krahulec B: Relationship between nephropathy, retinopathy, and autonomic neuropathy in patients with type I diabetes. *J Diabetic Complications* 4:188–192, 1990
- Mølgaard H, Christensen PD, Sørensen KE, Christensen CK, Mogensen CE: Association of 24-h cardiac parasympathetic activity and degree of nephropathy in IDDM patients. *Diabetes* 41:812–817, 1992
- Ewing DJ, Campbell IM, Clarke BF: The natural history of diabetic autonomic neuropathy. *Q J Med* 49:95–108, 1980
- Menzinger G, Spallone V, Maiello MR, Felici MG, Gambardella S: Mortality in diabetic autonomic neuropathy (Abstract). *Diabetes Res Clin Pract* 5 (Suppl. 1):S317, 1988
- Sampson MJ, Wilson S, Karagiannis P, Edmonds M, Watkins PJ: Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. *Q J Med* 75:635–646, 1990
- O'Brien IA, McFadden JP, Corrall RJM: The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. *Q J Med* 290:495–502, 1991
- Borch-Johnsen K, Kreiner S: Proteinuria: value as a predictor of cardiovascular mortality in insulin-dependent diabetes mellitus. *Br Med J* 294:1651–1654, 1987
- Lilja B, Nosslin B, Bergström B, Sundkvist G: Glomerular filtration rate, autonomic nerve function, and orthostatic blood pressure in patients with diabetes mellitus. *Diabetes Res* 2:179–181, 1985
- Winocour PH, Hanka D, Andersen DC: The relationship between autonomic neuropathy and urinary sodium and albumin excretion in insulin-treated diabetics. *Diabetic Med* 3:436–440, 1986
- Muller J, Barajas L: Electron microscopic and histochemical evidence for a tubular innervation in the renal cortex of the monkey. *J Ultrastruct Res* 41:533–549, 1972
- Bello-Reuss E, Pastoriza-Munoz E, Colindres RE: Acute unilateral renal denervation in rats with extracellular volume expansion. *Am J Physiol* 232:F26–F32, 1977
- Brenner BM, Zatz R, Ichikawa I: The renal circulations. In *The Kidney*. 3rd ed. Brenner BM, Rector FC, Eds. Philadelphia, PA, WB Saunders, 1986, p. 114–115
- Pelayo JC, Quan AH: Neurogenic control of renal function. In *Textbook of Nephrology*. 2nd ed. Massry SG, Glassock RJ, Eds. Baltimore, MD, Williams & Wilkins, 1989, p. 65–69
- Barinov EF, Kot AG, Onischenko NA: Changes in the local blood flows of the single kidney with partial impairment of the autonomic innervation. *Biul Eksp Biol Med* 107:283–285, 1989
- Wilcox CS, Aminoff MJ, Slater JDH: Sodium homeostasis in patients with autonomic failure. *Clin Sci Mol Med* 53:321–328, 1977
- Bannister R, Mathias C: Management of postural hypotension. In *Autonomic Failure*. 2nd ed. Bannister R, Ed. Oxford, UK, Oxford University Press, 1988, p. 575–577.
- Mancia G, Parati G: Experience with 24-hour ambulatory blood pressure monitoring in hypertension. *Am Heart J* 116:1134–1140, 1988
- Wiegmann TB, Herron KG, Chonko AM, MacDougall ML, Moore WV: Recognition of hypertension and abnormal blood pressure burden with ambulatory blood pressure recording in type I diabetes mellitus. *Diabetes* 39:1556–1560, 1990
- Benhamou PY, Halimi S, De Gaudemaris R, Boizel R, Pitot M, Siche JP, Bachelot I, Mallion JM: Early disturbances of ambulatory blood pressure load in normotensive type I diabetic patients with microalbuminuria. *Diabetes Care* 15:1614–1619, 1992
- Liniger C, Favre L, Adamec R, Pernet A, Assal J-Ph: Profil nyctéméral de la pression artérielle et de la fréquence cardiaque dans la neuropathie diabétique autonome. *Schweiz Med Wochenschr* 117:1949–1953, 1987
- Hornung RS, Mahler RF, Raftery EB: Ambulatory blood pressure and heart rate in diabetic patients: an assessment of autonomic function. *Diabetic Med* 6:579–585, 1989
- Felici MG, Spallone V, Maiello MR, Gatta R, Civetta E, Frontini S, Gambardella S, Menzinger G: Twenty-four hour blood pressure and heart rate profiles in diabetics with and without autonomic neuropathy. *Funct Neurol* 6:299–304, 1991
- Hansen KW, Mau Pedersen M, Marshall SM, Christiansen JS, Mogensen CE: Circadian variation of blood pressure in patients with diabetic nephropathy. *Diabetologia* 35:1074–1079, 1992
- Ewing DJ, Martyn CN, Young RJ, Clarke BF: The value of cardiovascular autonomic function tests: 10 years experience in diabetes. *Diabetes Care* 8:491–498, 1985
- Bellavere F, Bosello G, Fedele D, Cardone C, Ferri M: Diagnosis and management of diabetic autonomic neuropathy (Letter).

- Br Med J* 287:61, 1983
28. O'Brien E, Mee F, Atkins N, O'Malley K: Evaluation of the SpaceLabs 90202 non-invasive ambulatory recorder according to the AAMI Standard and BHS criteria. *J Hum Hypertens* 5:223–226, 1991
  29. Casadei R, Parati G, Pomidossi G, GropPELLI A, Trazzi S, Di Rienzo M, Mancia G: 24-h blood pressure monitoring: evaluation of SpaceLabs 5300 monitor by comparison with intra-arterial blood pressure recording in ambulant subjects. *J Hypertens* 6:797–803, 1988
  30. Mann S, Altman DG, Raftery EB, Bannister R: Circadian variation of blood pressure in autonomic failure. *Circulation* 68:477–483, 1983
  31. Bernardi L, Ricordi L, Lazzari P, Soldà PL, Calciati A, Ferrari MR, Vandea I, Finardi G, Fratino P: Impaired circadian modulation of sympatho-vagal activity in diabetes: a possible explanation for altered temporal onset of cardiovascular disease. *Circulation* 96:1443–1452, 1992
  32. Spallone V, Bernardi L, Ricordi L, Soldà PL, Maiello MR, Calciati A, Gambardella S, Fratino P, Menzinger G: Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. *Diabetes* 42:1745–1752, 1993
  33. Parving H-H, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnson M, Lauritzen M, Hougaard P, Lauritzen E: Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin-dependent diabetes. *Br Med J* 296:156–160, 1988
  34. Hilsted J: Pathophysiology in diabetic autonomic neuropathy: cardiovascular, hormonal and metabolic studies. *Diabetes* 31:730–737, 1982
  35. Bell GM, Reid W, Ewing DJ, Cumming AD, Watson ML, Doig A, Clarke BF: Abnormal diurnal urinary sodium and water excretion in diabetic autonomic neuropathy. *Clin Sci* 73:259–265, 1987
  36. Sundkvist G, Lilja B: Autonomic neuropathy predicts deterioration in glomerular filtration rate in patients with IDDM. *Diabetes Care* 16:773–779, 1993
  37. Cerasola G, Cottone S, D'Ignoto G, Grasso L, Mangano MT, Carapelle E, Nardi E, Andronico G, Fulantelli MA, Marcellino T, Seddio G: Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. *J Hypertens* 7 (Suppl. 6):S332–S333, 1989
  38. Giaconi S, Levanti C, Fommei E, Innocenti F, Seghieri G, Palla L, Palombo C, Ghione S: Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension. *Am J Hypertens* 2:259–261, 1989
  39. Christensen CK, Mogensen CE: The course of incipient diabetic nephropathy: studies of albumin excretion and blood pressure. *Diabetic Med* 2:97–102, 1985
  40. Torffvit O, Agardh E, Agardh CD: Albuminuria and associated medical risk factors: a cross-sectional study in 476 type 1 (insulin-dependent) diabetic patients. Part 1. *J Diabetic Complications* 5:23–28, 1991
  41. Krolewski AS, Barzilay J, Warram JH, Martin BC, Pfeifer M, Rand LI: Risk of early-onset proliferative retinopathy in IDDM is closely related to cardiovascular autonomic neuropathy. *Diabetes* 41:430–437, 1992